Category: Markets
Published: 2026-06-22T22:11:27.000Z
MoonLake Immunotherapeutics is conducting a public offering to raise $150 million through the sale of Class A Ordinary Shares and pre-funded warrants. The company intends to use the net proceeds, along with existing funds, to advance the research, development, and potential commercialization of its drug candidate, Sonelokimab (SLK), and for general corporate purposes. The offering also grants underwriters a 30-day option to purchase an additional $22.5 million in Class A Ordinary Shares.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.